Estrigenix welcomes new employees

Estrigenix Therapeutics welcomed two new employees this summer, Ms. Elaina Milkie and Dr. Dulanjali Thennakoon.

Ms. Elaina Milkie graduated with B.S. from the University of Wisconsin-Milwaukee (UWM) in May 2023, double majoring in Psychology and Biological Sciences. Elaina worked part time with Estrigenix in spring 2023 while completing her degree and transitioned to full time in June of this year. She is conducting in vivo testing of drug leads in mouse-models for menopause at Estrigenix facilities leased from UWM, and plans to continue her education in future in graduate school.

Dr. Dulanjali Thennakoon graduated with a Ph.D. in Organometallic Chemistry from Marquette University in July 2023. Her dissertation, entitled “Scope and Mechanistic Studies of Ruthenium Catalyzed C–C and CN Bond Activation Reactions” was conducted in the laboratory of Dr. Chae Yi. Some of this research was recently published in the journal Organometallics. Prior to matriculation at Marquette, Dulanjali obtained her B.Sc. in Chemistry from the University of Ruhuna, Sri Lanka. She is working on scale-up and prodrug synthesis at the Innovation Campus laboratory.